Thus, GLK, GLK-induced signaling molecules, or the GLK-induced AhR–ROR-γt complex can be a promising therapeutic target for patients with GLKhighIL-17Ahigh SLE. This evidence concerns the gene MAP4K3 and systemic lupus erythematosus.